Protalix BioTherapeutics Stock (AMEX:PLX), Quotes and News Summary

Q: What sector and industry does Protalix BioTherapeutics (PLX) operate in?

Protalix BioTherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.

Protalix BioTherapeutics Stock (AMEX: PLX) stock price, news, charts, stock research, profile.

Open	-
Close	-
Volume / Avg.	3.479K / 425.576K
Day Range	- - -
52 Wk Range	1.031 - 2.600
Market Cap	$83.580M
P/E Ratio	14.250
Dividend Yield	-
Exchange	AMEX
RSI	44
Short Interest	9.57%
Days to Cover	18.54

Recent News

Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Lisa Levin

Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics

The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult

Vandana Singh

Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil

Nabaparna Bhattacharya

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Rating

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Protalix BioTherapeutics (PLX) stock?

You can purchase shares of Protalix BioTherapeutics (AMEX: PLX) through any online brokerage.

View our list of the best stock brokerages.

Who are Protalix BioTherapeutics's (PLX) competitors?

Other companies in Protalix BioTherapeutics’s space includes: Anixa Biosciences (NASDAQ:ANIX), HOOKIPA Pharma (NASDAQ:HOOK), Curis (NASDAQ:CRIS), Connect Biopharma Hldgs (NASDAQ:CNTB) and Burning Rock Biotech (NASDAQ:BNR).

What is the target price for Protalix BioTherapeutics (PLX) stock?

The latest price target for Protalix BioTherapeutics (AMEX: PLX) was reported by HC Wainwright & Co. on Tuesday, November 14, 2023. The analyst firm set a price target for 10.00 expecting PLX to fall to within 12 months (a possible NaN% downside). 2 analyst firms have reported ratings in the last year.

Current Stock Price for Protalix BioTherapeutics (PLX)?

The stock price for Protalix BioTherapeutics (AMEX: PLX) is $ last updated .

Does Protalix BioTherapeutics (PLX) pay a dividend?

There are no upcoming dividends for Protalix BioTherapeutics.

When is Protalix BioTherapeutics (AMEX:PLX) reporting earnings?

Protalix BioTherapeutics’s Q2 earnings are confirmed for Monday, August 5, 2024.

Is Protalix BioTherapeutics (PLX) going to split?

There is no upcoming split for Protalix BioTherapeutics.

What sector and industry does Protalix BioTherapeutics (PLX) operate in?

Protalix BioTherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.

-

-

-

-

-

-

-

-

-

-

-

-

-

-